Matthew B. Harms, MD

Board Certifications: 
Neuromuscular Medicine, Clinical Neurophysiology, Neurology
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

ALS (Amyotrophic Lateral Sclerosis), Clinical Research, Lou Gehrig's Disease, Metabolic Myopathy, Mitochondrial Diseases, Muscular Dystrophy, Myofibrillar Myopathy, Myopathy, Peripheral Neuropathy

Academic Appointments

  • Associate Professor of Neurology

Matthew Harms, MD is an Associate Professor of Neurology. Dr. Harms received his A.B. in Biology summa cum laude from Harvard University in 1997, and his medical doctorate from the University of California San Francisco in 2003. He remained at San Francisco for neurology residency and served as Chief Resident in his final year. Dr. Harms completed neuromuscular medicine and clinical neurophysiology fellowships under the mentorship of Dr. Alan Pestronk at Washington University in St. Louis. His clinical training in neuromuscular diseases led him into the laboratory of Dr. Robert Baloh, where his post-doctoral research identified the genes responsible for two orphan human diseases- dominant spinal muscular atrophy with lower extremity predominance and limb-girdle muscular dystrophy type 1D.

Dr. Harms joined the neuromuscular medicine faculty at Washington University in 2009 with board certifications in neurology, clinical neurophysiology, and neuromuscular medicine. In 2011, Dr. Harms assumed leadership of the Washington University Neuromuscular Genetics Project and established his research laboratory to continue harnessing emerging genetic technologies to understand the causes of inherited neuromuscular diseases. The lab focuses on diseases of the motor neuron, including amyotrophic lateral sclerosis, spinal muscular atrophy, and the hereditary motor neuropathies, and where his efforts have helped identify more than 5 novel disease genes. Here at Columbia, he will continue these efforts, directing an international multi-site effort using whole genome and transcriptome sequencing to bring precision medicine to amyotrophic lateral sclerosis. His laboratory efforts will occur in both the Motor Neuron Center and the Institute for Genomic Medicine.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Location(s)

CUMC/Neurological Institute of New York
710 West 168th Street
New York, NY 10032
Primary

Insurance Accepted

For billing questions, please call (212) 342-4432.

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, University of California San Francisco School of Medicine
  • Internship: University of California San Francisco Medical Center
  • Residency: University of California San Francisco Medical Center
  • Fellowship: Barnes Jewish Hospital/Washington University
  • Fellowship: Barnes Jewish Hospital

Board Certifications

  • Neuromuscular Medicine
  • Clinical Neurophysiology
  • Neurology

Research

Grants

NEW YORK CITY CONSORTIUM FOR PRECISION MEDICINE (Federal Gov)

Mar 24 2018 - Feb 28 2023

NOVEL EXTRACELLULAR VESICLE AND MOLECULAR BIOMARKERS OF ENVIRONMENTAL EXPOSURE AND DISEASE PROGRESSION IN ALS (Federal Gov)

Sep 30 2018 - Sep 29 2020

ANSWER ALS: RETURN OF ALS RESULTS (Private)

Jan 1 2019 - Dec 31 2019

ANSWER ALS: RETURN OF RESULTS (ROAR) STUDY (Private)

Jan 1 2019 - Sep 30 2019

INTEGRATED GENOMICS IN CLINICAL ALS (Private)

Oct 1 2015 - Sep 30 2018

NEXT GENERATION SEQUENCING APPROACHES FOR NOVEL GENE DISCOVERY IN ALS (Federal Gov)

Sep 1 2016 - Jun 30 2017

TARGET ALS POSTMORTEM CORE (Private)

Jul 1 2016 - Jun 30 2017

EFFECT OF MEXILETINE ON CORTICAL HYPEREXCITABILITY IN SPORADIC AMYOTROPHIC LATERAL SCLEROSIS (SALS) (Private)

Jan 1 2016 - Jun 30 2017

MECHANISMS AND PHENOTYPES OF ALS CAUSED BY THE NOVEL ALS GENE TBK1 (Private)

Dec 1 2015 - Nov 30 2016

UNDERSTANDING CLINICAL PHENOTYPE AND COLLECTING BIOMARKER SAMPLES IN C9ORF72 ALS (Private)

Nov 1 2015 - Oct 31 2016

BIOGEN IDEC (Private)

Nov 1 2014 - Oct 31 2015

THE FRONTOTEMPORAL LOBAR DEGENERATION CLINICAL RESEARCH CONSORTIUM (Federal Gov)

Oct 1 2014 - Jul 31 2015

Selected Publications

O’Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AKMG, Ho R, Carmona S, Vit JP, Zarrow J, Kim K, Bell S, Harms MB, Miller TM, Dangler C, Underhill DM, Goodridge HS, Lutz CM, Baloh RH. C9ORF72 is required for proper machrophage and microglial function in mice. Science. 2016, Mar 18;351(6279):1324-9.

O'Rourke JG, Bogdanik L, Muhammad AK, Gendron TF, Kim KJ, Austin A, Cady J, Liu EY, Zarrow J, Grant S, Ho R, Bell S, Carmona S, Simpkinson M, Lall D, Wu K, Daughrity L, Dickson DW, Harms MB, Petrucelli L, Lee EB, Lutz CM, Baloh RH. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015, Dec 2;88(5):892-901.

Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, .. Harms MB, et al, Goldstein DB. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science, 2015, Mar 27,347(6229):1436-41.

*Weihl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, Allred P, Jockel-Balsarotti J, Pestronk A, Harms MB. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord. 2015, Apr;25(4):289-96.

*Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014, Apr;71(4):449-53.

Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo A, Rothstein JD; ITALSGEN Consortium, Drepper C, Sendtner M, Singleton AB, Taylor JP, Cookson MR, Restagno G, Sabatelli M, Bowser R, Chiò A, Traynor BJ. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014, May;17(5):664-6.

Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013, Nov 19;110(47):E4530-9.

δHarms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K, Carrell D, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, Mayeux R, Chakraverty S, Goate AM, δCruchaga C; NIA-LOAD/NCRAD Family Study Consortium. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol. 2013, Jun;70(6):736-41. δAuthors contributed equally.

Harms MB, Neumann D, Benitez BA, Cooper B, Carrell D, Racette BA, Perlmutter JS, Goate A, Cruchaga C. Parkinson disease is not associated with C9ORF72 repeat expansions. Neurobiol Aging. 2013, May;34(5):1519.e1-2. doi:10.1016

Harms MB, Ori-McKenney KM, Scoto M, Tuck EP, Bell S, Ma D, Masi S, Allred P, Al-Lozi M, Reilly MM, Miller LJ, Jani-Acsadi A, Pestronk A, Shy ME, Muntoni F, Vallee RB, Baloh RH. Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy. Neurology. 2012, May 29;78(22):1714-20.

Hakeda-Suzuki S, Ng J, Tzu J, Dietzl G, Sun Y, Harms M, Nardine T, Luo L, Dickson BJ. Rac function and regulation during Drosophila development. Nature. 2002, Mar 28;416(6879):438-42.

Ng J, Nardine T, Harms M, Tzu J, Goldstein A, Sun Y, Dietzl G, Dickson BJ, Luo L. Rac GTPases control axon growth, guidance and branching. Nature. 2002, Mar 28;416(6879):442-7.